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MyogeninMyogenesis involves the complex interplay between the down-regulation of non-muscle genes and the up-
regulation of muscle-speciﬁc genes. This interplay is controlled by the myogenic regulatory factors Myf5,
MRF4, MyoD and myogenin. To trigger the up-regulation of these muscle-speciﬁc factors, certain
environmental cues, such as the removal of serum, signal C2C12 myoblast cells to withdraw from cell
cycle, fuse and activate muscle-speciﬁc genes. Here, the level of ZBP-89 (zfp148), a Krüppel-like transcription
factor, has been shown to increase during myogenesis. Over-expression of ZBP-89, via adenoviral infection,
led to the enhancement of the myogenic program without requiring the removal of serum. Quantitative real-
time PCR and ChIP assays documented that ZBP-89 promoted the down-regulation of Pax7 coupled with the
up-regulation of MRF4 and MyoD to regulate C2C12 differentiation in vitro. In addition, ZBP-89 over-
expression up-regulated p21 and Rb while promoting the down-regulation of cyclinA and cyclinD1. In
converse, the diminution of ZBP-89 by siRNA promoted the retention of myogenic and cell cycle regulators at
myoblast levels resulting in a concomitant delay of the myogenic program. From these studies we conclude
that the transcription factor ZBP-89 plays an important role in the timing of the myogenic program.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Myogenesis can be viewed as a two-step process consisting of
determination, where precursor cells commit to a muscle lineage,
followed by differentiation of committed myoblasts to myotubes [1].
Complex mechanisms have evolved for controlling the proper timing of
gene expression during this process via two families of myogenic factors.
The basic Helix-Loop-Helix proteins (bHLH), Myf5, MRF4, MyoD and
myogenin, act by binding as heterodimers with E-box proteins to E-box
sequences (CANNTG) within muscle gene enhancers [1,2]. The temporal,
spatial, and regional expression of bHLH proteins contributes to terminal
differentiationof thevarious skeletalmuscles. The second setofmyogenic
factors, the MEF2 family, bind to AT-rich sequences, are common to all
muscle types, and function to potentiate the effect of bHLH proteins [3].
Thus, both transcription factor families are critical for the myogenic
program. The differentiation of C2C12 myoblasts in vitromimics many of
the gene expression patterns seen in the embryo and thus represents an
excellent model system to study myogenic gene regulation.
ThebHLH familymembers control theprocessesof determinationand
differentiation within a given somitic cell, the embryological origin of
skeletal muscle cells. These cells become committed to the muscle cell+1 804 828 1473.
ll rights reserved.lineagevia expressionof bothMyf5andMyoD. This expression is believed
tobe the committed step inmuscledevelopment, sincedisruptionof both
factors results in the absence of skeletal muscle [4–8]. However, MyoD
and Myf5 may serve partially redundant roles in determination as
deletion of either single gene does not eliminate muscle development,
although continued expression of Myf5 does prevent terminal differ-
entiation of C2C12 cells in vitro [8,9,10]. After somitic cells are determined
and migrate to skeletal muscle locations, the cells proliferate and
differentiate into striated myotubes where continued expression of
MyoD together withMRF4 expression is important. MRF4 andMyoD are
believed to play redundant roles in differentiation, although recent
evidence suggests that MRF4 may also play a role in determination [11].
Finally,myogenin is known to act downstreamof bothMyoDandMyf5, is
crucial to differentiation, and its absence results in a deﬁciency of muscle
ﬁbers despite muscle cell migration and commitment [12–13]. The
temporal expression of these factors during embryogenesis suggests
similar yet unique roles. Temporally, Myf5 is expressed ﬁrst in the
developingmyotome.MRF4displaysabiphasic expressionpatternduring
embryogenesis by up-regulating at embryonic day 9, tapering off by day
11.5 and then re-instating at day 16. MyoD expression begins at
embryonic day 11.5. Further understanding the individual role of each
factor duringmyogenesis is complicated by their ability to cross-regulate
each other's expression compounded by intricate promoter/enhancer
elements controlling spatial and temporal expression [14].
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ﬁnger transcription factor that binds to a GC-rich region and can
activate or repress transcription. ZBP-89 activates such genes as
human stromelysin [15], the T cell α- and β-receptor [16], p21waf1/cip1
[17] and the lymphocyte-speciﬁc protein tyrosine kinase [18]. ZBP-89
functions as a transcriptional repressor for the human gastrin [19],
human ornithine decarboxylase [20], rat β-enolase [21], bovine
adrenodoxin [22] epithelial neutrophil-activating peptide-78 (ENA-
78) [23], and vimentin [24] genes. ZBP-89 functions as an activator by
recruiting the histone acetyltransferase p300 to the p21 promoter to
up-regulate gene expression [25]. When ZBP-89 functions as a
repressor, it either competes with Sp1 for binding to the same or
overlapping sequences [19] or bind separately to its own DNA element
as found for the vimentin gene [24,26].
Recent evidence suggests ZBP-89may play a role in skeletal muscle
development. During mouse embryogenesis, ZBP-89 (Zfp148) mRNA
increases from day 12 to 14 in skeletal muscle and then declines after
birth [21]. While in adult mice, there are low levels of ZBP-89mRNA in
the adult heart and testis, intermediate levels in skeletal muscle and
spleen, and higher levels in brain, kidney, lung and liver [21].
Interestingly, in the adult rat equal levels of ZBP-89 mRNA exist in
heart, brain, spleen, lung, liver, skeletal muscle, kidney and testis [19].
A comparison of the ZBP-89 promoter region between the mouse and
human genes revealed at least 8 speciﬁc binding sites for Sp1, TCF-1,
Oct1, NF-κB, MyoD, Ets-1, Lyf-1 and ZBP-89 itself [27]. The ZBP-89
promoter contains MyoD and several MEF-2 binding sites, supporting
previous mRNA studies documenting an increase in ZBP-89 levels
during myogenesis. To further support a role for ZBP-89 in myogen-
esis, a ZBP-89 promoter-reporter construct containing the MyoD site
displayed a 3-fold increase in expression in C2C12 myotubes versus
myoblasts [27]. ZBP-89 is also important for blood development in
mice and zebraﬁsh, serving cooperative functions with GATA-1 and
FOG-1 to control erythroid development [28,29]. Here, we showed
that ZBP-89 over-expression led to enhancement of the myogenic
program via regulation of bHLH myogenic transcription factors and
cell cycle regulators important to C2C12 differentiation in vitro.
Moreover, these results were corroborated by siRNA elimination of
ZBP-89 expression.
2. Materials and methods
2.1. Cell cultures
C2C12 skeletal myoblast cells (ATCC CRL-1772) weremaintained in
high-glucose DMEM (Invitrogen) with glutamine, supplemented with
10% FBS (GM), penicillin (100 units/ml) and streptomycin (50 μg/ml).
Sub-conﬂuent cells were switched to differentiation medium (DM)
containing 1% FBS to initiate differentiation into myotubes.
2.2. RNA extraction and quantitative real-time PCR (qPCR)
For establishing a time course of RNA expression, C2C12 myoblast
cells were plated and harvested 24 h later as myoblast cells or
switched to DM and harvested every 24 h to follow differentiation in
vitro. For adenoviral over-expression, cells were plated for 24 h and
then left in GM or transferred to DM and then infected with Ad-empty,
Ad-β-gal or Ad-ZBP-89. Total RNA was extracted using the TRIzol
reagent (Invitrogen) 48 h after infection and prepared as mentioned
previously [30]. For qPCR ampliﬁcation, data acquisition and analyses
was carried out with a LightCycler instrument using a sequence-
detection system (model 7000; Applied Biosystems, Inc., Foster City,
CA). The qPCR mixture consisted of 10 μl of SYBR green master mix,
3 μl of cDNA and primers plus water to a ﬁnal vol of 20 μl. Primer
sequences used were as follows: for Rb 5′-AAGCTAGCA-
TGCCGCCCAAGCCCCG-3′ and 5′-TCTTCAACTCAAGCCTGGC-3′; for
p21 5′-ATGTCCAATCCTGGTGATGTCC-3′ and 5′-TCAGGGTTTTCTCTTG-CAGAAG-3′, for myogenin 5′-ACTCTTCGCCCCCGT-3′ and 5′-CCGCC-
CTGCCACTCAT-3′, for cyclinD1 5′-TCTACACTGACAACTCTATCCG-3′ and
5′-TAGCAGGAGAGGAAGTTGTTGG-3′, for ZBP-89 5′-CGCATT-
TAGAAGATGCGTCA-3′ and 5′-CCCCTCCTGCAAATTATCAA-3′, for Myf5
5′-TGTATCCCCTCACCAGAGGAT-3′ and 5′-GGCTGTAATAGTTCTCC-
ACCTGTT-3′, for MRF4 5′-CTACATTGAGCGTCTACA GGACC-3′ and 5′-
CTGAAGACTGCTGGAGGCTG-3′, for MyoD 5′-GACCTGCGCTTTTT
TGAGGACC-3′ and 5′-CAGGCCCACAGCAAGCAGCGAC-3′, for cyclinA1
5′-TTCCCCAA TGCTGGTTGA-3′ and 5′-AACCAAAATCCGTTGCTTCCT-3′,
for Pax7 5′-TGGAAGTG TCCACCCCTCTTGGC-3′ and 5′-ATCCA-
GACGGTTCCCTTTGTCGCC-3′. Gene ampliﬁcation was carried out as
follows: 95 °C for 10 min, followed by 50 cycles in 3 steps: 95 °C for
15 s, 55 °C for 30 s, and 68 °C for 45 s. At the end of the ampliﬁcation
cycles, dissociation curves were determined to rule out signal from
primer dimers and other nonspeciﬁc dsDNA species. Data was
normalized to U6 mRNA levels. Experiments were carried out in
triplicate on three separately isolated RNA samples and the standard
error was shown. The size of the PCR products was conﬁrmed by
analysis on a 2% agarose gel stained with ethidium bromide.
2.3. Plasmids and reagents
The Ad-ZBP-89 and a 2100 bp p21 promoter (in pGL3) were kindly
provided by Dr. Juanita Merchant (Univ. of Michigan, Ann Arbor, MI).
The cyclinD1 promoter construct was kindly provided by Dr. R.G.
Pestell (Northwestern, Chicago, Il). Protease inhibitor cocktail (P-
8340), monoclonal anti-vimentin antibody (V6630) and monoclonal
anti-Flag antibody (F-3165) were purchased from Sigma (St. Louis,
MO). Anti-tubulin (sc-9104) and anti-MHC (sc-20641) antibodies
were purchased from Santa Cruz Biotechnology.
2.4. Adenoviral infection and siRNA transfection
For adenoviral infection, C2C12 cells (5×104) were plated in each
well of a six-well plate, incubated overnight at 37 °C, media were
changed to either 1% FBS for myotubes or 10% FBS for myoblasts and
then infected with either adenoviral ﬂag-ZBP-89 (Ad-ZBP-89), Ad-
empty vector (Ad-empty) or Ad-β-galactosidase (Ad-β-gal) at an MOI
of 5. Cells were visualized at successive time points using a light
microscope and digital camera. All pictures were selected from three
independent experiments. For siRNA transfection, C2C12 cells
(8×104) were plated in each well of a 6-well plate, incubated
overnight at 37 °C and then the media were changed to either DM or
GM. Cells were then transfected with siControl (20 nm) or siZBP-89
(20 nm) (Dharmacon) using Dharmacon transfection reagent 2. Cells
were visualized at successive time points and pictures taken from
three separate experiments with a representative experiment shown.
2.5. DNA transfection and luciferase assays
C2C12 cells (2×105) were plated in each well of a six-well plate,
incubated overnight at 37 °C, mediawere changed to either GMor DM,
and then transiently transfected with plasmid DNA, either cyclinD1 or
p21 promoter constructs (2 μg), using the MIRUS DNA transfection
method (Fisher) and then co-infected with Ad-β-gal or Ad-ZBP-89.
The Renilla plasmid was co-transfected to serve as an internal control
for transfection efﬁciency. Myoblast cells were harvested 48 h after
transfection. Cell lysates were prepared via the freeze–thaw method.
Dual-luciferase assays were performed according to the established
protocol of Promega. All transfections were performed in triplicate
with at least two different DNA preparations for each plasmid.
2.6. Whole cell extract preparation and Western blotting
Whole cell extracts (WCE) were prepared from C2C12 cells infected
with Ad-ZBP-89, Ad-empty or Ad-β-gal. Cells were washed in cold 1×
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at 10 μl/1 ml (Sigma). After brief sonication, an equal volume of 1× PBS
was added to the lysate to reduce the SDS concentration to 2%. Lysates
were then centrifuged for 10min at 13,000 rpm, supernatants collected,
and protein concentration measured using the BioRad Dc Protein Assay
kit (BioRad, Hercules, CA). Equivalent amounts of protein (50 μg) were
boiled in 1× SDS sample buffer for 5 min and analyzed on 4–20%
gradient polyacrylamide gel (NuSep Inc., Austell, GA). Western blotting
was carried out as previously described [31]. Antibodies (1:1000) used
forWestern blots are as follows: anti-ﬂag, anti-β-tubulin, and anti-MHC.
2.7. BrdUrd staining and cell proliferation assays
C2C12 cells (1×103) were plated on coverslips and incubated
overnight at 37 °C. Cells were then infected with Ad-ZBP-89, Ad-
empty vector, or Ad-β-gal and incubated overnight at 37 °C. For siRNA
transfection, C2C12 cells were also plated on coverslips (1×103),
incubated overnight, and then transfected with Dharmafect reagent 2,
siControl or siZBP-89 and incubated overnight at 37 °C. 48 h after
treatment, cells were washed in 1×PBS brieﬂy and ﬁxed in 1:1
methanol–acetone at −20 °C for 10 min. The slides were washed
brieﬂy with 1×PBS, followed by permeabilization with 0.5% Tri-
tionX100 in 1× PBS for 30min. Cells were washed twice in 1×PBS and
blocked overnight in 1×PBS with BSA and ﬁsh gelatin. Coverslips
were incubated for an hour with an antibody to MHC. Cells were
washed three times in 1×PBS and then incubated with secondary
antibody. Finally, cells were washed three times in 1×PBS with 1%
Hoechst reagent. Cells were visualized using a ﬂuorescent microscope.
Cell nuclei versus nuclei stained were quantitated by counting 250
cells. All quantitationwas the result of three independent experiments
and subjected to a student's t-test analysis.
Cell proliferationwas monitored using theWST-1 reagent (Roche).
WST-1 is a colorimetric assay based on the cleavage of the tetrazolium
salt WST-1 to a formazan product by mitochondrial succinate-
tetrazolium reductase in viable cells thereby offering a method to
measure cell proliferation. C2C12 cells were plated in 96 well plates
(5×102) and incubated overnight at 37 °C. C2C12 cells were then
washed in 1×PBS and media switched to either GM or DM. Cells were
infected with Ad-ZBP-89, Ad-empty vector or Ad-β-gal and allowed to
incubate overnight at 37 °C. For successive days as indicated, media
were removed, cells were washed in 1×PBS and then 10 μl of WST-1
reagent was added to 100 μl of serum-free media and allowed to
incubate for 4 h. The optical density was read at 490 nm and results
were averaged from three separate experiments. For siRNA transfec-
tion, C2C12 cells were also plated in 96well plates (5×102), incubated
overnight andmedia changed as described previously. Cells were then
transfected with Dharmafect reagent 2, siControl or siZBP-89 and
allowed to incubate overnight at 37 °C. Cells were incubated with the
WST-1 reagent as mentioned above and the results were quantiﬁed
graphically.
2.8. ChIP assay
ChIP assays were performed as mentioned previously [26,30,32].
For qPCR, 2 μl out of the 20 μl of extracted DNAwas used in 50 cycles of
ampliﬁcation in 3 steps: 95 °C for 15 s, 55 °C for 30 s, and 68 °C for 45 s.
At the end of the ampliﬁcation cycles, dissociation curves were
determined to rule out signal from primer dimers and other
nonspeciﬁc dsDNA species. Data was normalized to IgG immunopre-
cipitated DNA levels. Experiments were carried out in triplicate and
one representative experiment was shown. The size of the PCR
products was conﬁrmed on a 2% agarose gel stained with ethidium
bromide. The primer sequences were as follows: for p21 (−282 to
+1) 5′-AATGTGTCCAGCGCACC-3′ and 5′-CCGGGCCTTTCTTTATGTT-3′,
for MyoD (proximal promoter region) 5′-CGCCCCCAGCCTCCCTTTC-
CAG-3′ and 5′-TGTCAGAGGTGTGGTGAAGAAA-3′, for MyoD enhancer(18–22 kb upstream of the transcriptional start site) [33] 5′-
CGGGGTCGGGATCCGGAC-3′ and 5′-GGTGTCGTA AACCCCCGTA-3′, for
myogenin upstream region 5′-CAAGACCCCTTCCCGTCCGTC-3′ and 5′-
CCTGCAGGCCTGCCCCTGG-3′, for myogenin proximal promoter region
(−147 to +1) 5′-GAATCACATGTAATCCACTGGA-3′ and 5′-
CGCCAACTGCTGGGTGCCA-3′, for MRF4 enhancer (20 kb upstream
of the transcriptional start site) [34] 5′-TTGTGTTAATCCCCAGTTGT-3′
and 5′-CTCCTCCTTGGCCTCTGACT-3′, for cyclinD1 proximal promoter
region 5′-GGTTTAAGAACAGGGTGTCC-3′ and 5′-GTTAAGCAGAGATCA-
AAGCC-3′, for Pax7 (−632 to −332) 5′-GAATTCCTCCCTTCAAGT-
CACC-3′ and 5′-TGAATGGGGCGGATCCGCCG-3′, Pax7 (−332 to +1)
5′-CCGGGATCGTCCCTCTCT-3′ and 5′-CAGGGCTGGACGG AGGAGAC-3′
[35].
3. Results
3.1. Over-expression of ZBP-89 leads to the enhancement of the myogenic
program
To analyze the effect of ZBP-89 expression on the myogenic
program, C2C12 myoblast cells were infected with adenovirus
encoding ZBP-89 attached to the Flag-epitope (Ad-ZBP-89) or as
negative controls adenovirus alone (Ad-empty) or containing β-
galactosidase (Ad-β-gal) under the control of the CMV promoter to
promote exogenous, sustained expression. Infected cells were either
maintained as myoblasts (MB) in GM or promoted to differentiate
to myotubes (MT) by a switch to DM (Fig. 1A). C2C12 myoblast cells
differentiated into myotubes by forming long structures of fused
cells detectable in culture whereas myoblast cells in GM remained
as single cells Myoblast cells alone or infected with either Ad-β-gal
or Ad-empty displayed the same visual pattern of single cells over
this time period (Fig. 1: MB+Ad-β-gal versus MB). By 48 h over-
expression of ZBP-89 induced long structures of fused cells even in
the presence of GM akin to myotubes or infected myotubes (Fig 1:
compare MB+Ad-ZBP-89 to MB). ZBP-89 over-expression was
conﬁrmed via Western blot analysis using a Flag-tag antibody
where β-tubulin served as a loading control (Fig. 1B). Endogenous
ZBP-89 protein levels during C2C12 differentiation could not be
monitored as a suitable, commercial antibody, which recognizes a
protein of the correct molecular weight at low endogenous levels is
not available. qPCR analysis of endogenous ZBP-89 mRNA levels at
successive time points after serum withdrawal demonstrated that
ZBP-89 mRNA levels rapidly increased during the ﬁrst 24 h in DM,
declined at 48 h, but gradually returned to the 24 h level by 120 h
(Fig. 1C). A similar biphasic expression pattern has been detected
for MRF4 during myogenesis [1,36]. The number of nuclei per ﬁber
increased in myoblasts infected with AD+ZBP-89 similar to
myotubes or infected myotubes (Fig. 1D). Staining for myosin
heavy chain (MHC) indicated that large numbers (85%) of myoblast
cells infected with Ad+ZBP-89 stain with MHC while myoblasts or
Ad-β-gal controls did not (Fig. 1E). Quantiﬁcation veriﬁed that 90%
of Hoechst stained myoblasts infected with Ad-ZBP-89 also
expressed MHC comparable to myotubes or Ad+ZBP-89 infected
myotubes (Fig. 1F)
3.2. Over-expression of ZBP-89 affected cell proliferation and suppressed
DNA synthesis
To determine if ZBP-89 over-expression affected cell proliferation,
BrdUrd incorporation into myoblasts or treated cells was compared to
similarly treatedmyotubes (Fig. 2A) [37]. Myoblastsmaintained in GM
for 24 h continued to proliferate as a large percentage of cells (N70%)
co-stained with DAPI and BrdUrd. Myoblast cells infected with Ad-β-
gal demonstrated similar proliferation rates. Myoblast cells switched
to DM for 24 h demonstrated a 15% reduction in BrdUrd incorporation.
Interestingly, after 24 h of Ad-ZBP-89 infection there were fewer
Fig.1.Over-expression of ZBP-89 enhances themyogenic program in C2C12 skeletal muscle cells. (A) C2C12myoblast cells (MB)were plated at 1×104/well, incubated in GM (DMEM
plus 10% FBS) or differentiated to myotubes (MT) in DM (DMEM plus 1% FBS) plus either Ad-β-gal, Ad-empty vector or Ad-ZBP-89 for 24 and 48 h, and visualized using a light
microscope at 20×magniﬁcation. Representative ﬁelds from 3 independent experiments are shown. (B) Western blot analyses of WCEs (50 μg) isolated from C2C12 cells as grown in
part A for 0, 12, 24, 48 and 96 h as described in Materials and methods. Antibodies used for immunoblotting (IB) are indicated at dilutions of 1:1000 and β-tubulin is included as a
loading control. (C) qPCR analysis of endogenous ZBP-89 mRNA levels in MBs plated for 24 h and harvested or MTs switched to DM and harvested at the indicated times. Details of
qPCR conditions are discussed in Materials and methods. The y-axis represents the relative ZBP-89 mRNA levels normalized to U6 expression. Results are graphed with MB set as 1×
and are the average of three separate experiments performed in triplicate with bars representing the standard error of the means (S.E.). (D) Graphical analysis of cells infected with
Ad-β-gal, Ad-empty or Ad-ZBP-89 and stained with Hoechst to determine the number of nuclei per muscle ﬁber. Results are from three separate, independent experiments. (E) MBs,
MTs and Ad-infected cells were co-stained with Hoechst and MHC and then visualized via ﬂuorescence microscopy. Results are representative of three independent experiments.
(F) Quantitation of microscopy results from part E. Results are graphed as the percentage of Hoechst stained cells that also express MHC.
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cells. Whether kept as myoblasts in high serum or allowed to
differentiate to myotubes, only 50% of Ad-ZBP-89 infected cells
remained proliferative at 24 h.In addition, the growth of myoblasts, myotubes or cells infected
with either Ad-β-gal or Ad-ZBP-89 was compared using the
proliferation reagent, WST-1 (Fig. 2B). Both myoblasts and control
cells continued to proliferate for 4 days tapering off by day 5. Myoblast
Fig. 2. Over-expression of ZBP-89 in C2C12 myoblasts suppresses DNA synthesis and
proliferation. (A) C2C12 MBs were plated at 1×104 and incubated in GM or DM and
infected with either Ad-ZBP-89 or Ad-β-gal for 24 h. DNA synthesis was monitored
following incubation of cells with BrdUrd for 5 h. Cells were grown on coverslips,
followed by ﬁxation with methanol–acetone and anti-BrdUrd staining. Cell nuclei were
visualized by DAPI. BrdUrd-labeled cells were counted relative to the number of nuclei.
The results presented were derived from the counting of at least 250 cells from three
independent experiments and bars represent the S.E. (B) C2C12 MBs were plated at
5×102 and incubated in GM or DM infected with either Ad-ZBP-89 or Ad-β-gal. Cell
growth was measured at 1, 2, 3, 4, and 5 days using the WST-1 proliferation reagent
incubated for 4 h and recorded as the optical density (OD) at 490 nm (y axis). The mean
from three independent experiments was graphed.
Fig. 3. ZBP-89-dependent modulation of myogenic regulatory factor expression. (A)
qPCR analysis of endogenous MRF4, Pax7, and MyoD mRNA levels in C2C12 MBs, MTs,
MBs plus Ad-β-gal, Ad-empty vector, or Ad-ZBP-89, or MTs plus Ad-ZBP-89 isolated 48 h
after infection as described in Materials and methods. The y-axis represents the relative
mRNA levels normalized to U6 expression and set relative to MBs as 1×. Results are the
average of three separate experiments performed in triplicate with bars representing
the S.E. (B) qPCR analysis of endogenous myogenin mRNA levels as described in part A.
(C) ChIP analysis of ZBP-89 binding over the Pax7 promoter region (−632 to −333),
the MRF4 enhancer region [34], the MyoD enhancer region [33], and the myogenin
proximal promoter region (−332 to +1) in MBs, MTs, and MBs plus Ad-ZBP-89 or Ad-
β-gal 48 h after infection as described in Materials and methods. Results obtained with
IgG versus Flag-tagged antibody immunoprecipitation are shown.
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or myotubes plus Ad-ZBP-89 in DM.
3.3. ZBP-89 modulated the bHLH myogenic regulatory factors
The effect of ZBP-89 on the expression of bHLH myogenic regulatory
factors was measured during C2C12 differentiation (Fig. 3). C2C12 cells
were plated for 24 h and infected with either Ad-ZBP-89, Ad-empty
vector or Ad-β-gal. Cells were harvested 48 h later and RNA isolated to
determine the subsequent effect of ZBP-89 over-expression on the timed
expression of several bHLH myogenic factors. Pax7 is a determination
factor that down-regulates during differentiation and myotube fusion
[10]. ThemRNA levels of Pax7 declined inmyoblasts with the addition of
Ad-ZBP-89 akin tomyotubeswhile infectionwith either Ad-empty or Ad-
β-gal had no effect (Fig. 3A). On the other hand Ad-ZBP-89 expression in
myoblasts induced MRF4 expression by 9-fold (Fig. 3A). Infection with
Ad-ZBP-89 also increasedMyoDexpression inmyoblasts akin tomyotube
levels [38] (Fig. 3A). Myogenin is another bHLH regulatory factor known
to substantially increase during differentiation. The addition of Ad-ZBP-
89 greatly up-regulated myogenin expression 1000-fold in myoblasts
mimicking levels seen inmyotubeswith an additional 1.7-fold increase inmyotubes plus Ad-ZBP-89 compared to myotubes alone (Fig. 3B). Thus
ZBP-89 appeared to induce the myogenic program via modulating the
expression of crucial bHLH myogenic regulatory factors.
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myotubes, or myoblasts plus Ad-β-gal or Ad-ZBP-89 to determine if
ZBP-89 was directly binding to speciﬁc DNA elements within the
promoters of these target genes. Experiments with myoblasts infectedFig. 4. ZBP-89 regulates cell cycle protein expression and binds to DNA control regions of the p
in Fig. 3A. mRNAwas normalized to U6mRNA expression. Results are graphed withMBs set a
representing the standard errors of the mean. (B) A p21 promoter (full promoter containin
transiently transfected into C2C12 cells and reporter gene activity measured in MBs, MBs+A
average of three separate experiments performed in triplicate on two separate plasmid preps
promoter inMBs, MTs, andMBs plus Ad-β-gal or Ad-ZBP-89 as described in part A. (D) A cycli
reporter gene activity measured as described in Materials and methods. Results are the avera
and bars represent the S.E.with Ad-empty vector ormyotubes plus Ad-ZBP-89were not reported,
since the same result was detected as with myoblasts plus Ad-β-gal or
Ad-ZBP-89, respectively. Interestingly, ZBP-89 was found to bind to a
region of the Pax7 promoter (Fig. 3C) previously suggested to contain21 promoter. (A) qPCR analysis of endogenous p21, Rb, cyclinD1 and cyclinA as prepared
s 1× and are the average of three separate experiments performed in triplicatewith bars
g a E-box, ZBP-89 and Sp1 binding sites as shown) luciferase (p21Luc) construct was
d-β-gal or Ad-ZBP-89 and MTs as described in Materials and methods. Results are the
and bars represent the S.E. (C) ChIP analysis of ZBP-89 binding over the endogenous p21
nD1 (full promoter) luciferase construct was transiently transfected into C2C12 cells and
ge of three separate experiments performed in triplicate on two separate plasmid preps
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supported our previous results (Fig. 3A) and suggested that ZBP-89
must be acting as a transcriptional repressor to promote the down-
regulation of Pax7 during C2C12 myogenesis. ZBP-89 was also found
to bind the MRF4 enhancer region (Fig. 3C) [34], substantiating our
previous results (Fig. 3A). Interestingly, ZBP-89 did not bind the MyoD
minimal promoter region (data not shown), but bound an upstream
enhancer region known to contain an H4TF-1 element. Previously, a
similar H4TF-1 element within the vimentin gene was shown to bind
ZBP-89 (Fig. 3C) [32,33]. However, we did not detect ZBP-89 binding
to either the myogenin minimal promoter (Fig. 3C) or an upstream
myogenin enhancer (data not shown), both of which contain known
GC-rich regions. Thus, ChIP assays corroborate that ZBP-89 was
speciﬁcally binding to DNA elements within the promoters of some of
these target genes, but not all, further supporting the selectivity of
these ChIP results.
3.4. ZBP-89 affected the expression of downstream targets of the
myogenic regulatory factors
In addition to the timed activation of key myogenic regulatory
factors, skeletal muscle cells permanently withdraw from cell cycle
during differentiation. Thus, the effect of ZBP-89 on crucial cell cycle
regulators such as p21, Rb, cyclinD1 or cyclinA was investigated (Fig.
4). MyoD is known to indirectly activate p21 expression during
myogenesis [39,40]. p21 mRNA levels, a known target for ZBP-89
regulation in other cell lines [25], increased 5.7-fold after infection
with Ad-ZBP-89 while the negative controls (Ad-empty and Ad-β-gal)
had no effect on p21 expression (Fig. 4A). Rb protein levels also
increased during myogenesis to promote cell cycle withdrawal [42].
Myoblasts or infected controls demonstrated low levels of Rb mRNA;
however, Rb levels were increased in myotubes (6-fold), and even
more in myoblasts or myotubes infected with Ad-ZBP-89. Conversely,
cyclinAmRNA levels declined duringmyogenesis andwith infection of
Ad-ZBP-89 whereas both negative controls (infection with Ad-empty
vector or Ad-β-gal) demonstrated little effect on cyclinA mRNA levels
(Fig. 4A). Finally, cyclinD1 down-regulation is also one of the key cell
cycle regulators required to decline during myogenesis [4,37,43].
CyclinD1 mRNA was extremely low in myoblasts and myotubes
infected with Ad-ZBP-89 (Fig 4A). Thus, ZBP-89 also apparently either
directly or indirectly regulated key cell cycle regulatory proteins
important for the myogenic program.Fig. 5. ZBP-89modulates MHC expression during myogenesis. (A)Western blot analysis
of WCEs (50 μg) isolated from C2C12 cells as grown in panel 1A for 12, 24, 48, 72 and
96 h as described in Materials and methods. Antibodies used for immunoblotting (IB)
are indicated at dilutions of 1:1000. β-tubulin served as a loading control.Previously, ZBP-89 has been shown to bind to the p21 promoter and
activate its expression [25]. p21 expression is known to be up-
regulated via Western blots and transient transfection analysis in the
C2C12 cell line during differentiation [37,39]. Here, the effect of ZBP-89
expressionwasmonitored on the activity of a full-length p21 promoter
luciferase construct (p21Luc2100 bp) in myoblasts, myotubes or
duplicate cultures infected with Ad-β-gal or Ad-ZBP-89 (Fig. 4B). As
discussed earlier, transfection of myoblasts plus Ad-empty vector or
myotubes plus Ad-ZBP-89 were not included, since identical results
were obtainedwithmyoblasts plus Ad-β-gal ormyotubes plusAd-ZBP-
89, respectively (Fig. 3). Transient transfection of p21Luc intomyotube
cells resulted in a 1.6-fold increase in relative luciferase activity over
that level detected in myoblast cells. Addition of Ad-ZBP-89 further
increased p21 promoter activity 2-fold in myoblast cells while there
was no effect with infection of Ad-β-gal alone. ChIP assays veriﬁed
ZBP-89 bindingon the p21 promoter (Fig. 4C). A cyclinD1 full promoter
luciferase constructwas also assayed via transient transfection analysis
in C2C12 cells (Fig. 4D). Myoblast and myoblast+Ad-β-gal cells
demonstrated high reporter gene activity while myotubes and
myoblast plus Ad-ZBP-89 demonstrated a 7.5-fold decrease in relative
luciferase activity. ChIP assays were performed to determine if ZBP-89
binds directly to the cyclinD1 promoter during myogenesis (data not
shown). No evidence for ZBP-89 binding to the cyclinD1 promoter was
detected; thus, ZBP-89 must act through an indirect mechanism to
repress cyclinD1 expression during C2C12 myogenesis. MHC is a
known downstream target of MyoD and myogenin. MHC levels were
assayed viaWestern blot analysis in extracts prepared fromC2C12 cells
as indicated. As expected MHC levels increased substantially in
myotubes and myoblasts+Ad-ZBP-89 while no expression was
detected in myoblasts or myoblast+Ad-β-gal (Fig. 5). Tubulin levels
remained constant serving as a loading control. In summary, ZBP-89
modulated the expression of cell cycle regulators and an important
downstream protein target (MHC) of the myogenic program.
3.5. Elimination of ZBP-89 via siRNA approaches
By a number of criteria, we have shown that ZBP-89 enhanced the
myogenic program. We next determined the effect of ZBP-89
elimination via siRNA approaches. C2C12 myoblast cells were
transfected with Dharmacon siControl or siZBP-89 and observed at
24 and 48 h (Fig. 6A). Myoblasts with siControl mimicked the same
visual pattern seen earlier for myoblast cells as there was continued
proliferation without the formation of long fused structures. Elimina-
tion of ZBP-89 appeared to also result in proliferation similar to that
seen for the siControl. qPCR analysis of RNA isolated frommyoblasts or
myotubes plus siZBP-89 veriﬁed that ZBP-89 mRNA levels were barely
detectable after siZBP-89 treatment, while ZBP-89 mRNA levels in the
siControl showed normal levels of myoblast or myotube ZBP-89mRNA
expression, respectively (Fig. 6B). Further investigation into the effects
of ZBP-89 elimination on the myogenic program was examined via
Hoechst and MHC staining (Fig. 6C). Elimination of ZBP-89 in
myotubes delayed myogenesis as there was a substantial decline in
the number of MHC stained cells despite the removal of serum
(Figs. 6C and D).
3.6. Effect of siZBP-89 on C2C12 proliferation
The proliferation capacity of myoblast, myotube, and similar cells
transfected with siRNAs was assayed via BrdUrd incorporation and the
proliferation reagentWST-1 (Fig. 7).Myoblast cells in GMcontinued to
proliferate when stained with BrdUrd as a large percentage of cells
(72%) co-stained with DAPI and BrdUrd (Fig. 7A) as seen previously
(Fig. 2A). Myoblast cells treated with siControl or siZBP-89 demon-
strated similar proliferation rates. The addition of siZBP-89 to
myoblasts contrasted to earlier results (Fig. 2A)where over-expression
of Ad-ZBP-89 reduced myoblast proliferation from 72% to 50% even in
Fig. 6. Elimination of ZBP-89 via siRNA in C2C12 myoblast cells. (A) C2C12 MBs were plated at 8×104, incubated in GM or DM, transfected with siControl or siZBP-89 for 24 and 48 h,
and visualized using a light microscope. Representative ﬁelds are shown from three independent experiments. (B) qPCR analysis of endogenous ZBP-89 mRNA levels prepared as
described in Fig. 1C. The relative ZBP-89 mRNA levels were normalized to U6 expression and graphed relative to MBs set as 1×. Results are the average of three separate experiments
performed in triplicate with bars representing the S.E. (C) MB, MT and si transfected cells were co-stained with Hoechst and MHC and then visualized via ﬂuorescence microscopy. A
representative image from three independent experiments is shown. (D) Quantitation of microscopy results from part C graphed as the percentage of Hoechst stained cells that also
express MHC.
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myoblasts remained constant with the addition of siZBP-89 similar
to that of the myoblast controls. However, proliferation decreased to
60% for myotubes switched to DM for 24 h analogous to those results
displayed by myotubes treated with siControl or siZBP-89. Interest-
ingly, the addition of siZBP-89 to myotubes did not overcome this
decrease in proliferation probably due to the reduced level of serum in
DM. In addition, cell growth was measured using the WST-1
proliferation reagent. Again, myoblast cells treated with either the
transfection reagent alone, with the siControl or with siZBP-89 all
demonstrated similar proliferation rates that mimicked the rates seen
for myoblast cells alone (Fig. 7B). Concurrently, myotubes transfectedwith the three aforementioned reagents mimicked the growth rates
seen for myotube cells (Fig. 7C).
3.7. Elimination of ZBP-89 affected myogenic and cell cycle regulatory
factors
C2C12myoblastswere transiently transfectedwith siZBP-89 and RNA
was isolated 48 h after transfection to monitor the levels of myogenic
factors analyzed earlier. Pax7 mRNA levels declined in myotubes com-
pared to myoblasts (Fig. 8A). An analogous decrease was noted in myo-
blasts or myotubes transfected with siZBP-89 but not with the siControl.
Perhaps low levels of ZBP-89 are required for some factor to up-regulate
Fig. 7. Effect of siZBP-89 on C2C12 proliferation. (A) C2C12 MBs were plated at 1×104
and incubated in GM alone or transfected with either transfection reagent alone
(Dharmafect), siControl or siZBP-89 for 24 h and DNA synthesis was determined
following incubation of cells with BrdUrd for 5 h as described previously in Fig. 2A. (B)
C2C12 MBs were plated at 5×102 and incubated in GM for MBs and transfected with
transfection reagent alone, siControl or siZBP-89. Cell growthwas determined at 1, 2, 3, 4,
and 5 days after infection by the addition of theWST-1 proliferation reagent for 4 h. The
mean from three independent experiments was graphed. (C) C2C12 MBs were plated at
5×102 and incubated in GM for MBs or switched to DM for MTs and transfected with
either transfection reagent alone, siControl or siZBP-89 as described in B.
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contrast, MRF4 levels were low inmyoblasts and increased at least 5-fold
inmyotubes. Similar resultswere seen upon transfection of the siControl.
Transfection with siZBP-89 resulted in MRF4 levels equivalent to those
detected in myoblast cells; thus, elimination of ZBP-89 prevented MRF4up-regulation.MyoDmRNA levelswere also low inmyoblastswhile there
was a substantial increase in myotubes. Similar results were obtained
with the siControl. Bothmyoblast ormyotube cells treatedwith siZBP-89
showed statistically signiﬁcant decreases in MyoD mRNA levels. Ap-
parently elimination of ZBP-89 overcomes the ability of serum with-
drawal to promote the up-regulation of MyoD. Similar results were
obtained for myogenin (Fig. 8B) and p21 (Fig. 8D). Thus, treatment with
siZBP-89 blocked the normal increased expression of MRF4, MyoD, p21
and myogenin during C2C12 differentiation.
mRNA levels for additional cell cycle regulators were analyzed upon
treatment with siZBP-89 (Fig. 8) and compared to previous results
(Fig. 4). Myoblasts demonstrated low levels of Rb mRNA which in-
creased in myotubes, analogous to results obtained previously (Fig. 8D
compared to Fig. 4A). siZBP-89 drastically reduced Rb expression to
levels even lower than those detected inmyoblasts or controls thereof. A
substantial decrease in cyclinA mRNA levels was noted in myotubes or
myotubes plus the siControl compared to myoblasts and its similar
control (Fig. 8C). Elimination of ZBP-89 further increased cyclinA levels
in both myoblasts or myotubes. Previously, cyclinD1 mRNA levels were
shown to decline after infectionwith ZBP-89; therefore, we determined
what effect elimination of ZBP-89 would have on cyclinD1 (Fig. 8D).
CyclinD1 mRNA levels were high in myoblasts and demonstrated a
substantial decrease in myotubes. Interestingly, the level of cyclinD1
mRNA in myoblasts or myotubes treated with siZBP-89 was 1/2 that
level of mRNA expressed in myoblast cells. Thus, the blockage of
myogenesis by the elimination of ZBP-89 led to low levels of Rb mRNA
and corresponding higher levels of cyclinA1 or cyclin D1 mRNA in both
myoblasts and myotubes treated with siZBP-89.
4. Discussion
This current study presents compelling evidence that the tran-
scription factor ZBP-89 is differentially expressed during C2C12
differentiation and contributes substantially to the C2C12 myogenic
program. Infection with Ad-ZBP-89 induced the fusion of C2C12
myoblast cells in growth media and inhibited cell proliferation (Figs. 1
and 2). Over-expression of ZBP-89 induced the bHLH regulatory
factors MRF4, myogenin, and MyoD, and the cell cycle regulatory
proteins p21 and Rb (Figs. 3, 4 and 5), factors known to contribute to
the differentiation of myoblasts into myotubes [37,44,45,46]. ZBP-89
down-regulated Pax7 (Fig. 3), as well as cyclinD1 and cyclinA (Fig. 5),
all factors known to decline during myogenesis [43]. However,
elimination of ZBP-89 via siRNA down-regulated the bHLH proteins
and cell cycle regulators that were increased with ZBP-89 over-
expression. Thus, ZBP-89 enhanced the myogenic program in C2C12
cells by affecting the expression of a variety of muscle-speciﬁc
transcription factors and cell cycle regulatory proteins.
These results suggest the following model for the role of ZBP-89
in C2C12myogenesis (Fig. 9). FromqPCRandChIP analyses, ZBP-89 can
bind to the Pax7 promoter to repress Pax7 transcription (Fig. 3). Pax7
has been shown by others to up-regulate Myf5 expression and in turn
together these factors inhibit C2C12 differentiation [10]. Thus, ZBP-89
repression of Pax7 mRNA expression would enhance myogenic
progression. To further promote differentiation, ZBP-89 binds and
activates the MRF4 enhancer and as well as a H4TF-1 element within
the MyoD enhancer (Fig. 3) [33,34]. MyoD acts downstream to
indirectly induce p21 expression by a previously unknown mechan-
ism. [40]. Here,we show that ZBP-89 can bind to the p21 promoter via a
binding site at −274 adjacent to a known E-box sequence (Fig. 4).
Perhaps ZBP-89 enhances the recruitment of MyoD to the p21 pro-
moter. In nonmuscle cell lines, ZBP-89 recruits p300 to the p21 pro-
moter; therefore, MyoD, ZBP-89 and p300 may be part of a multi-
protein complex to activate p21 expression during differentiation [25].
p21 and p57 then up-regulate myogenin expression [41]. Via a dif-
ferent mechanism, MyoD also activates myogenin expression during
differentiation [40]. In summary, ZBP-89 indirectly up-regulates
Fig. 8. Elimination of ZBP-89 affects expression of bHLH regulatory factors and cell cycle proteins (A) qPCR analysis of endogenous MRF4, Pax7 and MyoD mRNA levels prepared as
described in Fig. 3A. The relative mRNA levels were normalized to U6 expression and graphed relative to MBs set as 1×. Results are the average of three separate experiments
performed in triplicate with bars representing the S.E. (B) qPCR analysis of endogenous myogenin mRNA levels prepared as mentioned in part A. (C) qPCR analysis of endogenous
cyclinA mRNA levels prepared as mentioned in part A. (D) qPCR analysis of endogenous p21, Rb and cyclinD1 mRNA levels prepared as mentioned in part A.
Fig. 9. Model of ZBP-89 regulation during myogenesis. Proposed model of ZBP-89
regulation during in vitro myogenesis of C2C12 cells.
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upstream and can assist myoblast differentiation by down-regulating
Pax7 and up-regulating MRF4, MyoD and p21.
By increasing the bHLH myogenic regulatory factors, ZBP-89 also
indirectly regulated Rb and cyclinD1. The phosphorylation status of Rb
correlates with cell proliferation where differentiation and hypopho-
sphorylation is associated with the lack of cell growth [44]. Rb and
MyoD have been shown to directly interact to contribute to Rb
hypophosphorylation, suppression of myoblast cell growth, exit from
cell cycle, and cellular differentiation [47]. Rb also cooperates with
MyoD to activate the transcriptional activation domain (TAD) of MEF2
[4]. Thus, activation of Rb expression is part of the mechanism
whereby ZBP-89 can contribute to myoblast differentiation. In
contrast, cyclinD1 declines during myogenesis where it is the
predominant cyclin controlling progression through the G1 phase by
interacting with cdk4 [4,37,43]. Forced expression of cyclinD1 inhibitsmyogenesis [43,46,48]. ZBP-89 contributed indirectly to cyclinD1
down-regulation during myogenesis, since ChIP analysis demon-
strated no detectable levels of ZBP-89 bound to relevant regions of
the cyclinD1 promoter (from −635 to transcriptional start) (Fig. 4).
1154 M. Salmon et al. / Biochimica et Biophysica Acta 1793 (2009) 1144–1155ZBP-89 might regulate the expression of a yet unknown protein that
regulates cyclinD1 expression. The indirect down-regulation of
cyclinD1 is another mechanism whereby ZBP-89 contributes to
muscle differentiation.
Several possibilities may explain how ZBP-89 functions as a
transcriptional activator and repressor during differentiation. Previous
studies suggest ZBP-89 is modiﬁed by post-translational modiﬁcations
[49]. ZBP-89 contains multiple phosphorylation sites for a number of
different kinases such as CamKII and PKC-ζ, which are important to the
myogenic program [50]. We and others have detected multiple ZBP-89
bands in Western blots of extracts prepared from non-muscle cells
grown on 32P-orthophosphate (Wu unpublished observation) [19,30].
Thus, ZBP-89 could be selectively phosphorylated duringmyogenesis by
a kinase such as CaMKII. CaMKII has been shown to phosphorylate and
regulate HDAC4 localization to promote differentiation [50]. In non-
muscle cells ZBP-89 repression involves HDAC1; however, similar
studies have yet to be conducted in muscle cells [26]. The ability of
ZBP-89 to function as an activator or repressor could depend on direct
modiﬁcation of ZBP-89 or its required co-activators or co-repressors. In
each case, post-translational modiﬁcations might initiate this process at
the onset of serumwithdrawal. ZBP-89 and these factors could act in an
auto-regulatory loop, since the mouse ZBP-89 (Zfp148) promoter
contains a number of putative myogenic factor binding sites for MEF-2
and MyoD and promoter-Luc constructs demonstrated increased
activity in myotubes versus myoblast cells [27]. These myogenic factors
andZBP-89 could act in a regulatory loop to further promote eachother's
expression during differentiation. Furthermore, ZBP-89 has been shown
to be selectively sumoylated at two separate locations controlling its
function as a repressor versus a weak activator of transcription [49].
However, in this case regulation by sumoylation was shown for DNA
binding sites where ZBP-89 and Sp1 compete for binding to the same
DNA element and not for examples where Sp1 and ZBP-89 bind to
separate elements. Further studies are required to determine how post-
translationalmodiﬁcations control the abilityof ZBP-89 to function as an
activator or repressor during C2C12 myogenesis.
While this study has been conducted within the C2C12 myogenic
cell line, its correlation to in vivo embryogenesis warrants further
investigation. ZBP-89 over-expression or elimination via siRNA
regulates the activity of many proteins that are key regulators of
the myogenic program and cell cycle withdrawal, i.e. MRF4, MyoD,
cyclinD1, Rb and p21. The manipulation of ZBP-89 during embry-
ogenesis could have a widespread effect on skeletal muscle
differentiation and embryogenesis, since knockout of ZBP-89 results
in embryonic lethality by day 10.5. Previous Northern blots suggested
that ZBP-89 mRNA is up-regulated at day 12–14 in mouse embryos
and then declines in newborns and adults once differentiation is
complete [21]. In our study notable differences in ZBP-89 mRNA
levels were found during differentiation. These results were sup-
ported by previous studies from a group that found a 3-fold increase
in the activity of a transiently transfected ZBP-89 promoter construct
in C2C12 myotubes compared to myoblasts [27]. However, this same
group found there were no changes in ZBP-89 mRNA levels via
Northern blot analysis [21]. Our results may differ due to the
sensitivity of qPCR compared to Northern blots where it is difﬁcult
to accurately quantitate the total level of the three ZBP-89 mRNA
isoforms. Our ZBP-89 primers were designed to a conserved 5′-
region, thus all ZBP-89 mRNA molecules are included in our
measurements. Since ZBP-89 can be either an activator or a repressor
of gene expression, ZBP-89 protein levels are not required to decline
during differentiation to decrease expression of a target gene like β-
enolase [21]. Changes in ZBP-89 activity may occur by protein
modiﬁcation and/or differential interactionwith other known ZBP-89
partners such as Sp1, HDAC1 or p300 on different promoters
[19,25,26,49]. Furthermore, preliminary data suggested ZBP-89 also
affects cardiac development (Salmon unpublished observation) [21]
and hematopoiesis [28,29]. Finally, ZBP-89 may also be important ingamete production as suggested by mouse knockout studies,
although this result may be dependent on the knockout mechanism
[28,51]. In conclusion ZBP-89 appears to play key roles in several
developmental programs and conditional knockouts are required to
further investigate these mechanisms in vivo. However, ZBP-89 plays
a major role in differentiation of the C2C12 myogenic cell line, which
likely extends to myogenesis in vivo.
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